<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "6: depend heavily upon", fill: "#93ccea"},
{source: "6: depend heavily upon", target: "6: human tissue", fill: "#93ccea"},
{source: "6: human tissue", target: "6: tissue from", fill: "#93ccea"},
{source: "6: tissue from", target: "6: timely manner will", fill: "#93ccea"},
{source: "6: timely manner will", target: "6: interfere with", fill: "#93ccea"},
{source: "6: interfere with", target: "6: distribute allografts", fill: "#93ccea"},
{source: "6: depend heavily upon", target: "8: addition due", fill: "#b31b1b"},
{source: "8: addition due", target: "8: scarce tissues", fill: "#b31b1b"},
{source: "8: scarce tissues", target: "8: allografts", fill: "#b31b1b"},
{source: "8: allografts", target: "8: particularly", fill: "#b31b1b"},
{source: "8: addition due", target: "14: regulatory", fill: "#df73ff"},
{source: "14: regulatory", target: "14: disease transmission issues facing", fill: "#df73ff"},
{source: "14: disease transmission issues facing", target: "14: industry as well as", fill: "#df73ff"},
{source: "14: industry as well as", target: "14: negative publicity", fill: "#df73ff"},
{source: "14: negative publicity", target: "14: impact on", fill: "#df73ff"},
{source: "14: impact on", target: "14: contracts with recovery", fill: "#df73ff"},
{source: "14: regulatory", target: "28: additional distributors", fill: "#00827f"},
{source: "28: additional distributors", target: "28: new allografts", fill: "#00827f"},
{source: "28: new allografts", target: "28: technologies as well as", fill: "#00827f"},
{source: "28: technologies as well as", target: "28: technologies", fill: "#00827f"},
{source: "28: technologies", target: "28: existing allografts", fill: "#00827f"},
{source: "28: existing allografts", target: "28: new market segments", fill: "#00827f"},
{source: "28: new market segments", target: "28: geographical areas", fill: "#00827f"},
{source: "28: additional distributors", target: "32: regulatory influences", fill: "#03c03c"},
{source: "32: regulatory influences", target: "32: United States ", fill: "#03c03c"},
{source: "32: United States ", target: "32: fundamental", fill: "#03c03c"},
{source: "32: regulatory influences", target: "98: intensely competitive", fill: "#ff43a4"},
{source: "98: intensely competitive", target: "100: competitors", fill: "#6495ed"},
{source: "100: competitors", target: "100: distribution", fill: "#6495ed"},
{source: "100: distribution", target: "100: resources than", fill: "#6495ed"},
{source: "100: competitors", target: "START_HERE", fill: "#6495ed"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Allotransplantation">Allotransplantation</a></td>
      <td>Allotransplant (allo- meaning "other" in Greek) is the transplantation of cells, tissues, or organs to a recipient from a genetically non-identical donor of the same species. The transplant is called an allograft, allogeneic transplant, or homograft.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bone_grafting">Bone grafting</a></td>
      <td>Bone grafting is a surgical procedure that replaces missing bone in order to repair bone fractures that are extremely complex, pose a significant health risk to the patient, or fail to heal properly. Some small or acute fractures can be cured without bone grafting, but the risk is greater for large fractures like compound fractures.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Organ_transplantation">Organ transplantation</a></td>
      <td>Organ transplantation is a medical procedure in which an organ is removed from one body and placed in the body of a recipient, to replace a damaged or missing organ.  The donor and recipient may be at the same location, or organs may be transported from a donor site to another location.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Skin_grafting">Skin grafting</a></td>
      <td>Skin grafting, a type of graft surgery, involves the transplantation of skin. The transplanted tissue is called a skin graft.Surgeons may use skin grafting to treat:\n\nextensive wounding or trauma\nburns\nareas of extensive skin loss due to infection such as necrotizing fasciitis or purpura fulminans\nspecific surgeries that may require skin grafts for healing to occur - most commonly removal of skin cancersSkin grafting often takes place after serious injuries when some of the body's skin is damaged.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Nerve_allograft">Nerve allograft</a></td>
      <td>Nerve allotransplantation (allo- means "other" in Greek) is the transplantation of a nerve to a receiver from a donor of the same species. For example, nerve tissue is transplanted from one person to another.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Chronic_allograft_nephropathy">Chronic allograft nephropathy</a></td>
      <td>Chronic allograft nephropathy (CAN) is a kidney disorder which is the leading cause of kidney transplant failure, occurring months to years after the transplant.\n\n\n== Symptoms and signs ==\nCAN is characterized by a gradual decline in kidney function and, typically, accompanied by high blood pressure and hematuria.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Allograft_inflammatory_factor_1">Allograft inflammatory factor 1</a></td>
      <td>Allograft inflammatory factor 1 (AIF-1) also known as ionized calcium-binding adapter molecule 1 (IBA1) is a protein that in humans is encoded by the AIF1 gene.\n\n\n== Gene ==\nThe AIF1 gene is located within a segment of the major histocompatibility complex class III region.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Anterior_cruciate_ligament">Anterior cruciate ligament</a></td>
      <td>The anterior cruciate ligament (ACL) is one of a pair of cruciate ligaments (the other being the posterior cruciate ligament) in the human knee. The two ligaments are also called "cruciform" ligaments, as they are arranged in a crossed formation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cardiac_allograft_vasculopathy">Cardiac allograft vasculopathy</a></td>
      <td>Cardiac allograft vasculopathy (CAV) is a progressive type of coronary artery disease in people who have had a heart transplant. As the donor heart has lost its nerve supply there is typically no chest pain, and CAV is usually detected on routine testing.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/HCL_Technologies">HCL Technologies</a></td>
      <td>HCL Technologies (Hindustan Computers Limited) is an Indian multinational information technology (IT) services and consulting company headquartered in Noida. It is a subsidiary of HCL Enterprise.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renaissance_Technologies">Renaissance Technologies</a></td>
      <td>Renaissance Technologies LLC, also known as RenTech or RenTec, is an American hedge fund based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analysis. Their signature Medallion fund is famed for the best record in investing history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Technologies">United Technologies</a></td>
      <td>United Technologies Corporation (UTC) was an American multinational conglomerate headquartered in Farmington, Connecticut.  It researched, developed, and manufactured products in numerous areas, including aircraft engines, aerospace systems, HVAC, elevators and escalators, fire and security, building automation, and industrial products, among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Lumen_Technologies">Lumen Technologies</a></td>
      <td>Lumen Technologies, Inc. (formerly CenturyLink) is an American \ntelecommunications company headquartered in Monroe, Louisiana, that offers communications, network services, security, cloud solutions, voice, and managed services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology">Information technology</a></td>
      <td>Information technology (IT) is the use of computers to create, process, store, retrieve, and exchange all kinds of electronic data and information. IT is typically used within the context of business operations as opposed to personal or entertainment technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territories, 326 Indian reservations, and nine minor outlying islands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_states_and_territories_of_the_United_States">List of states and territories of the United States</a></td>
      <td>The United States of America is a federal republic consisting of 50 states, a federal district (Washington, D.C., the capital city of the United States), five major territories, and various minor islands. The 48 contiguous states and Washington, D.C., are in North America between Canada and Mexico.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/President_of_the_United_States">President of the United States</a></td>
      <td>The president of the United States (POTUS) is the head of state and head of government of the United States of America. The president directs the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Congress">United States Congress</a></td>
      <td>The United States Congress is the legislature of the federal government of the United States. It is bicameral, being composed of a lower body, the House of Representatives, and an upper body, the Senate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Navy">United States Navy</a></td>
      <td>The United States Navy (USN) is the maritime service branch of the United States Armed Forces and one of the eight uniformed services of the United States. It is the largest and most powerful navy in the world, with the estimated tonnage of its active battle fleet alone exceeding the next 13 navies combined, including 11 U.S. allies or partner nations as of 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_presidents_of_the_United_States">List of presidents of the United States</a></td>
      <td>The president of the United States is the head of state and head of government of the United States, indirectly elected to a four-year term by the American people through the Electoral College. The office holder leads the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_dollar">United States dollar</a></td>
      <td>The United States dollar (symbol: $; code: USD; also abbreviated US$ or U.S. Dollar, to distinguish it from other dollar-denominated currencies; referred to as the dollar, U.S. dollar, American dollar, or colloquially buck) is the official currency of the United States and several other countries. The Coinage Act of 1792 introduced the U.S. dollar at par with the Spanish silver dollar, divided it into 100 cents, and authorized the minting of coins denominated in dollars and cents.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Republican_Party_(United_States)">Republican Party (United States)</a></td>
      <td>The Republican Party, also referred to as the GOP ("Grand Old Party"), is one of the two major contemporary political parties in the United States, along with its main historic rival, the Democratic Party.\nThe GOP was founded in 1854 by anti-slavery activists who opposed the Kansas–Nebraska Act, which allowed for the potential expansion of chattel slavery into the western territories.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Democratic_Party_(United_States)">Democratic Party (United States)</a></td>
      <td>The Democratic Party is one of the two major contemporary political parties in the United States. It was founded in 1828 by supporters of Andrew Jackson, making it the world's oldest active political party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Marine_Corps">United States Marine Corps</a></td>
      <td>The United States Marine Corps (USMC), also referred to as the United States Marines, is the maritime land force service branch of the United States Armed Forces responsible for conducting expeditionary and amphibious operations through combined arms, implementing its own infantry, artillery, aerial, and special operations forces. The U.S. Marine Corps is one of the eight uniformed services of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_backlinking">Competitor backlinking</a></td>
      <td>Competitor backlinking is a search engine optimization strategy that involves analyzing the backlinks of competing websites within a vertical search. The outcome of this activity is designed to increase organic search engine rankings and to gain an understanding of the link building strategies used by business competitors.By analyzing the backlinks to competitor websites, it is possible to gain a benchmark on the number of links and the quality of links that is required for high search engine rankings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitors_for_the_Crown_of_Scotland">Competitors for the Crown of Scotland</a></td>
      <td>When the crown of Scotland became vacant in September 1290 on the death of the seven-year-old child Queen Margaret, 13 claimants to the throne came forward. Those with the most credible claims were John Balliol, Robert Bruce, John Hastings and Floris V, Count of Holland.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_of_athletics">Sport of athletics</a></td>
      <td>Athletics is a group of sporting events that involves competitive running, jumping, throwing, and walking. The most common types of athletics competitions are track and field, road running, cross country running, and racewalking.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_female_fitness_and_figure_competitors">List of female fitness and figure competitors</a></td>
      <td>This is a list of female fitness and figure competitors.\n\n\n== A ==\nJelena Abbou\n\n\n== B ==\nLauren Beckham\nAlexandra Béres\nSharon Bruneau\n\n\n== C ==\nNatalie Montgomery-Carroll\nJen Cassetty\nKim Chizevsky\nSusie Curry\n\n\n== D ==\nDebbie Dobbins\nNicole Duncan\n\n\n== E ==\nJamie Eason\nAlexis Ellis\n\n\n== F ==\nAmy Fadhli\nJaime Franklin\n\n\n== G ==\nAdela García \nConnie Garner\nElaine Goodlad\nTracey Greenwood\nOksana Grishina\n\n\n== H ==\nMallory Haldeman\nVanda Hădărean\nJen Hendershott\nSoleivi Hernandez\nApril Hunter\n\n\n== I ==\n\n\n== J ==\nTsianina Joelson\n\n\n== K ==\nAdria Montgomery-Klein\nAshley Kaltwasser\n\n\n== L ==\nLauren Lillo\nMary Elizabeth Lado\nTammie Leady\nJennifer Nicole Lee\nAmber Littlejohn\nJulie Lohre\nJenny Lynn\n\n\n== M ==\nTimea Majorová\nLinda Maxwell\nDavana Medina\nJodi Leigh Miller\nChisato Mishima\n\n\n== N ==\nKim Nielsen\n\n\n== O ==\n\n\n== P ==\nVicky Pratt\nElena Panova\nChristine Pomponio-Pate\nCathy Priest\n\n\n== Q ==\n\n\n== R ==\nMaite Richert\nCharlene Rink\nKelly Ryan\n\n\n== S ==\nErin Stern\nCarol Semple-Marzetta\nKrisztina Sereny\nTrish Stratus (Patricia Anne Stratigias)\n\n\n== T ==\nKristi Tauti\nJennifer Thomas\n\n\n== U ==\n\n\n== V ==\nLisa Marie Varon\n\n\n== W ==\nLatisha Wilder\nTorrie Wilson\nLyen Wong\nJenny Worth\nNicole Wilkins\n\n\n== Y ==\n\n\n== Z ==\nMarietta Žigalová\nMalika Zitouni\n\n\n== See also ==\nList of female bodybuilders\n\n\n== References ==\nThere has been a rise in the number of women wanting to compete as fitness models.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_Dancing_with_the_Stars_(American_TV_series)_competitors">List of Dancing with the Stars (American TV series) competitors</a></td>
      <td>Dancing with the Stars is an American reality television show in which celebrity contestants and professional dance partners compete to be the best dancers, as determined by the show's judges and public voting. The series first broadcast in 2005, and thirty complete seasons have aired on ABC. During each season, competitors are progressively eliminated on the basis of public voting and scores received from the judges until only a few contestants remain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_Group">Competitor Group</a></td>
      <td>Competitor Group, Inc. (CGI) is a privately held, for-profit, sports marketing and management company based in Mira Mesa, San Diego, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Round-robin_tournament">Round-robin tournament</a></td>
      <td>A round-robin tournament (or all-play-all tournament) is a competition in which each contestant meets every other participant, usually in turn. A round-robin contrasts with an elimination tournament, in which participants are eliminated after a certain number of losses.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>REGENERATION TECHNOLOGIES INC      Item 1A    RISK FACTORS          An <font color="blue">investment</font> in our <font color="blue"><font color="blue">common stock</font> involves</font> a high degree of risk</td>
    </tr>
    <tr>
      <td>You should     consider each of the risks and <font color="blue"><font color="blue">uncertainties</font> described</font> in this section and     all of the other information in this document before deciding to invest in     our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Any of the <font color="blue">risk factors</font> we describe below <font color="blue">could severely</font>     harm our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The market     price  of  our  common  stock  could  decline if any of these risks or     <font color="blue">uncertainties</font> develop <font color="blue">into actual events</font></td>
    </tr>
    <tr>
      <td>You may lose all or part of the     money you paid to buy our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend heavily upon</font> a limited number of sources of <font color="blue">human tissue</font>, and any     failure  to  obtain  <font color="blue">tissue from</font> these sources in a <font color="blue">timely manner will</font>     <font color="blue">interfere with</font> our ability to process and <font color="blue">distribute <font color="blue">allografts</font></font></td>
    </tr>
    <tr>
      <td>The limited supply of <font color="blue">human tissue</font> has at times limited our growth, and may     not be sufficient to meet our future needs</td>
    </tr>
    <tr>
      <td>In addition, due to seasonal     changes  in  mortality  rates, some <font color="blue">scarce tissues</font> that we use for our     <font color="blue">allografts</font> are at times in <font color="blue">particularly</font> short supply</td>
    </tr>
    <tr>
      <td>Other factors, some of     which are unpredictable, such as <font color="blue">negative publicity</font> and <font color="blue"><font color="blue">regulatory</font> actions</font>     in our <font color="blue">industry also</font> can <font color="blue">unexpectedly reduce</font> the <font color="blue">available supply</font> of tissue</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on donor recovery groups</font> for our <font color="blue">human tissue</font> supply</td>
    </tr>
    <tr>
      <td>Donor recovery     groups are part of <font color="blue">relatively complex <font color="blue">relationships</font></font></td>
    </tr>
    <tr>
      <td>They <font color="blue">provide support</font> to     <font color="blue">donor families</font>, are <font color="blue">regulated by</font> the FDA, and are often <font color="blue">affiliated</font> with     hospitals, <font color="blue">universities</font> or organ <font color="blue">procurement</font> groups</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">relationships</font> with</font>     donor recovery groups, which are critical to our supply of tissue, can be     <font color="blue">affected by <font color="blue">relationships</font></font> they have with other <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>Any negative     impact  of  the  <font color="blue">regulatory</font> and <font color="blue">disease <font color="blue">transmission</font> issues facing</font> the     industry, as well as the <font color="blue">negative publicity</font> that these issues create, could     have an <font color="blue">impact on</font> our ability to negotiate favorable <font color="blue">contracts with recovery</font>     groups</td>
    </tr>
    <tr>
      <td>Southeast  Tissue Alliance, or SETA, our <font color="blue">largest donor recovery</font> group,     supplied us with approximately 25prca of our total <font color="blue">human tissue</font> for the year     ended <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>Our <font color="blue">three largest recovery groups together supplied</font>     approximately 52prca of our <font color="blue">total tissue</font> for the year ended <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>If we were to lose any one of these <font color="blue">three sources</font> of tissue, the <font color="blue">impact on</font>     our operating results would be material</td>
    </tr>
    <tr>
      <td>We  cannot be sure that our supply of <font color="blue">human tissue</font> will continue to be     <font color="blue">available at current levels</font> or will be sufficient to meet our needs</td>
    </tr>
    <tr>
      <td>If we     are <font color="blue">no longer able</font> to obtain <font color="blue">tissue from</font> our <font color="blue">current sources sufficient</font> to     meet our needs, we may not be able to <font color="blue">locate additional replacement sources</font>     of <font color="blue">tissue on <font color="blue">commercially reasonable terms</font></font>, if at all</td>
    </tr>
    <tr>
      <td>Any <font color="blue">interruption</font> of     our business caused by the need to <font color="blue">locate additional sources</font> of <font color="blue">tissue would</font>     <font color="blue"><font color="blue">significant</font>ly hurt</font> our revenues</td>
    </tr>
    <tr>
      <td>We expect our <font color="blue"><font color="blue">revenues would</font> decline</font> in     proportion to any decline in <font color="blue">tissue supply</font></td>
    </tr>
    <tr>
      <td>12     ______________________________________________________________________    [48]Table of <font color="blue">Contents       </font>If we fail to maintain our <font color="blue">existing strategic <font color="blue">relationships</font></font> or are unable to     identify <font color="blue">additional distributors</font> of our implants, our <font color="blue">revenues may decrease</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">currently derive</font> the majority of our <font color="blue">revenues through</font> our <font color="blue">relationships</font>     <font color="blue">with two companies</font>, Medtronic Sofamor Danek, or MSD and Exactech, Inc</td>
    </tr>
    <tr>
      <td>For     the year ended <font color="blue">December </font>31, 2005, we derived approximately 60prca and 5prca of our     <font color="blue">revenues from <font color="blue">distribution</font> by</font> MSD and Exactech, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>MSD  provides  nearly  all  of  the instrumentation, surgeon training,     <font color="blue"><font color="blue">distribution</font> assistance</font> and <font color="blue">marketing materials</font> for our line of spinal     <font color="blue">allografts</font></td>
    </tr>
    <tr>
      <td>MSD <font color="blue">materially reduced</font> its <font color="blue">orders from us during</font> the past year</td>
    </tr>
    <tr>
      <td>If our <font color="blue">relationship with</font> MSD is terminated or <font color="blue">further reduced</font> for any reason     and  we  are  unable  to  replace the <font color="blue">relationship with</font> other means of     <font color="blue">distribution</font>, we <font color="blue">would suffer</font> a material decrease in revenues</td>
    </tr>
    <tr>
      <td>We may need to obtain the assistance of <font color="blue">additional distributors</font> to market     and distribute our new <font color="blue">allografts</font> and <font color="blue">technologies</font>, as well as to market and     distribute our existing <font color="blue">allografts</font> and <font color="blue">technologies</font> to <font color="blue">new market segments</font>     or <font color="blue">geographical areas</font></td>
    </tr>
    <tr>
      <td>We may not be able to find <font color="blue">additional distributors</font>     who will agree to and <font color="blue"><font color="blue">successfully</font> market</font> and distribute our <font color="blue">allografts</font> and     <font color="blue">technologies</font> on <font color="blue">commercially reasonable terms</font>, if at all</td>
    </tr>
    <tr>
      <td>If we are unable     to establish additional <font color="blue">distribution</font> <font color="blue">relationships</font> on favorable terms, our     <font color="blue">revenues may decline</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">third party payors fail</font> to <font color="blue">provide appropriate levels</font> of <font color="blue">reimbursement</font>     for the use of our implants, our <font color="blue">revenues would</font> be <font color="blue">adversely affected</font></td>
    </tr>
    <tr>
      <td>Political, economic and <font color="blue">regulatory</font> influences are subjecting the healthcare     industry in the <font color="blue">United States </font>to <font color="blue">fundamental</font> change</td>
    </tr>
    <tr>
      <td>Any new federal or     state <font color="blue">legislation could</font> result in <font color="blue">significant</font> changes in the <font color="blue">availability</font>,     delivery, pricing or payment for <font color="blue">healthcare services</font> and products</td>
    </tr>
    <tr>
      <td>While we     <font color="blue">cannot predict</font> what form any <font color="blue">new legislation will</font> take, it is possible that     any <font color="blue">significant</font> healthcare legislation, if adopted, could lower the amounts     paid to us for our services, which would decrease our revenues</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">revenues depend largely on</font> the <font color="blue">reimbursement</font> of patients’ medical     <font color="blue">expenses by government health care programs</font> and <font color="blue">private health insurers</font></td>
    </tr>
    <tr>
      <td><font color="blue">Governments  </font>and  private  insurers closely examine <font color="blue">medical procedures</font>     <font color="blue">incorporating</font> new <font color="blue">technologies</font> to determine whether the procedures will be     covered by payment, and if so, the level of payment which may apply</td>
    </tr>
    <tr>
      <td>We     cannot be sure that <font color="blue">third party payors will continue</font> to <font color="blue">reimburse us</font> or     <font color="blue">provide payment at levels which will</font> be profitable to us</td>
    </tr>
    <tr>
      <td>If we fail to maintain the <font color="blue">high <font color="blue">processing standards</font></font> that our implants     require or if we are unable to develop <font color="blue">processing <font color="blue">capacity</font> as</font> required, our     <font color="blue">commercial opportunity will</font> be reduced or eliminated</td>
    </tr>
    <tr>
      <td>Our  implants  require  careful  <font color="blue">calibration</font> and precise, high-quality     processing</td>
    </tr>
    <tr>
      <td><font color="blue">Achieving </font>precision and <font color="blue">quality control</font> requires skill and     <font color="blue">diligence by</font> our personnel</td>
    </tr>
    <tr>
      <td>If we fail to achieve and maintain these high     <font color="blue">processing standards</font>, including avoiding processing errors, design defects     or component failures:           •   we could be forced to recall, withdraw or suspend <font color="blue">distribution</font> of our     implants;           •   our implants and <font color="blue">technologies</font> could fail <font color="blue">quality assurance</font> and     <font color="blue">performance tests</font>;           •   production and <font color="blue">deliveries</font> of our <font color="blue">implants could</font> be delayed or     cancelled; and           •   our <font color="blue">processing costs could increase</font></td>
    </tr>
    <tr>
      <td>Further,  to  be  successful,  we will need to manage our <font color="blue">human tissue</font>     processing  <font color="blue">capacity</font>  related  to  tissue  recovery and demand for our     <font color="blue">allografts</font></td>
    </tr>
    <tr>
      <td>It may be <font color="blue">difficult</font> for us to match our processing <font color="blue">capacity</font> to     <font color="blue">demand due</font> to problems related to yields, <font color="blue">quality control</font> and assurance,     tissue <font color="blue">availability</font>, adequacy of <font color="blue">control policies</font> and procedures, and lack     of <font color="blue">skilled personnel</font></td>
    </tr>
    <tr>
      <td>If we are unable to process and produce our implants     on  a timely basis, at acceptable quality and costs, and in sufficient     quantities, or if we experience <font color="blue">unanticipated <font color="blue">technological</font> problems</font> or     delays in processing, it will reduce our revenues and increase our cost per     <font color="blue">allograft processed</font></td>
    </tr>
    <tr>
      <td>13     ______________________________________________________________________    [49]Table of <font color="blue">Contents       </font>Our allograft and <font color="blue">xenograft implants</font> and <font color="blue">technologies</font> could become subject     to <font color="blue">significant</font>ly greater regulation by the FDA, <font color="blue">which could disrupt</font> our     business</td>
    </tr>
    <tr>
      <td>The  FDA  could identify     <font color="blue">deficiencies</font> in <font color="blue">future inspections</font> of our <font color="blue">facilities</font> or <font color="blue">promulgate future</font>     <font color="blue">regulatory</font>  rulings  that  could  disrupt  our  business,  hurting our     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>For example, in mid-2001, the FDA reviewed our BioCleanse^® process after     the FDA <font color="blue">raised concerns about</font> the process</td>
    </tr>
    <tr>
      <td><font color="blue">While the FDA </font>concluded that the     compliance portion of its review of our BioCleanse^® process in January 2002     and determined we were in <font color="blue">compliance with existing</font> FDA <font color="blue">requirements</font> and that     no <font color="blue">regulatory</font> action was warranted, the <font color="blue">possibility always</font> exists that the     FDA <font color="blue">could raise concerns with</font> these or other aspects of our business</td>
    </tr>
    <tr>
      <td>The     FDA’s decision, that no <font color="blue">regulatory</font> action was warranted, does not <font color="blue">constitute</font>     a <font color="blue">formal approval</font> of our BioCleanse^® process and the FDA is free to raise     the same or similar concerns in the future</td>
    </tr>
    <tr>
      <td>If any of our <font color="blue">allografts</font> fall under the FDA’s <font color="blue">definitions</font> of “more than     <font color="blue">minimally manipulated</font> or indicated for <font color="blue">nonhomologous use</font>,” we would be     required  to  obtain medical device approval or clearance or biologics     licenses, which could require <font color="blue">clinical testing</font></td>
    </tr>
    <tr>
      <td><font color="blue">Disapproval </font>of our license     <font color="blue">applications</font> and restricted <font color="blue">distribution</font> of any of our <font color="blue">allografts</font>, which may     become subject to pre-market approval, may result</td>
    </tr>
    <tr>
      <td>The FDA could require     post-market  testing  and  surveillance to monitor the effects of such     <font color="blue">allografts</font>, could restrict the commercial <font color="blue">applications</font> of these <font color="blue">allografts</font>,     and <font color="blue">could conduct periodic inspections</font> of our <font color="blue">facility</font> and our suppliers’     <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>Delays <font color="blue">encountered during</font> the FDA <font color="blue">approval process could shorten</font>     the <font color="blue">patent protection period during which</font> we have the exclusive right to     commercialize such <font color="blue">technologies</font> or <font color="blue">could allow others</font> to come to <font color="blue">market with</font>     similar <font color="blue">technologies</font> before us</td>
    </tr>
    <tr>
      <td>FDA <font color="blue">regulations</font> of <font color="blue">human cellular</font> and tissue-based products, titled “Good     Tissue Practices,” went into full force as of May 2005</td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font>     cover all stages of allograft processing, from <font color="blue">procurement</font> of tissue to     <font color="blue">distribution</font> of final <font color="blue">allografts</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">regulations</font> may increase <font color="blue">regulatory</font>     <font color="blue">scrutiny within</font> our industry and lead to <font color="blue">increased <font color="blue">enforcement</font> action which</font>     affects  the conduct of our business</td>
    </tr>
    <tr>
      <td>In addition, the effect of these     <font color="blue">regulations</font> may have a <font color="blue">significant</font> effect <font color="blue">upon recovery agencies which</font>     <font color="blue">supply us with tissue</font> and increase the cost of <font color="blue">recovery activities</font></td>
    </tr>
    <tr>
      <td>Any such     <font color="blue">increase would translate into increased costs</font> to us, as we compensate the     recovery agencies based on their cost of recovery</td>
    </tr>
    <tr>
      <td>Other <font color="blue">regulatory</font> entities include state <font color="blue">agencies with statutes covering</font>     <font color="blue">tissue banking</font></td>
    </tr>
    <tr>
      <td>Of <font color="blue">particular relevance</font> to our business are <font color="blue">regulations</font>     issued by Florida, New York, California and Maryland</td>
    </tr>
    <tr>
      <td>Most states do not     currently have <font color="blue">tissue banking</font> <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>However, <font color="blue">recent <font color="blue">incidents</font></font> of     allograft related <font color="blue">infections</font> in the <font color="blue">industry may stimulate</font> the <font color="blue">development</font>     of  regulation  in  other  states</td>
    </tr>
    <tr>
      <td>It is possible that others may make     <font color="blue">allegations <font color="blue">against us</font></font> or <font color="blue">against donor recovery groups</font> or <font color="blue">tissue banks</font>,     including those with which we have a relationship, about non-compliance with     applicable FDA <font color="blue">regulations</font> or other <font color="blue">relevant statutes</font> and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Allegations </font>like these could cause <font color="blue">regulators</font> or other <font color="blue">authorities</font> to take     <font color="blue">investigative</font> or other action, or could cause <font color="blue">negative publicity</font> for our     business and our industry</td>
    </tr>
    <tr>
      <td>Some  of  our implants in <font color="blue">development</font> will contain tissue derived from     animals, commonly referred to as xenografts</td>
    </tr>
    <tr>
      <td><font color="blue">Xenograft </font>implants are medical     devices that are subject to pre-market approval or clearance by the FDA We     may not receive FDA approval or clearance to <font color="blue">market <font color="blue">new implants</font> as</font> we     attempt  to  expand  the  quantity of <font color="blue">xenograft implants</font> available for     <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">allograft industry</font> is subject to <font color="blue">additional local</font>, state, federal and     <font color="blue">international government</font> <font color="blue">regulations</font> and any increased <font color="blue">regulations</font> of our     current or future activities could <font color="blue">significant</font>ly increase the cost of doing     business, <font color="blue">thereby reducing</font> our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Some aspects of our business are subject to <font color="blue">additional local</font>, state, federal     or <font color="blue">international regulation</font></td>
    </tr>
    <tr>
      <td>Changes in the laws or <font color="blue">new interpretations</font> of     <font color="blue">existing laws could negatively affect</font> our business, revenues or                                           14     ______________________________________________________________________    [50]Table of <font color="blue">Contents       </font>prospects, and increase the <font color="blue">costs associated with conducting</font> our business</td>
    </tr>
    <tr>
      <td>In particular, the <font color="blue">procurement</font> and <font color="blue">transplantation</font> of <font color="blue">allograft tissue</font> is     subject to <font color="blue">federal regulation under</font> the National Organ Transplant Act, or     NOTA, a criminal statute that prohibits the purchase and sale of human     organs,  including  bone and other tissue</td>
    </tr>
    <tr>
      <td>NOTA permits the payment of     reasonable  expenses  associated  with the transportation, processing,     preservation, <font color="blue">quality control</font> and storage of <font color="blue">human tissue</font>, which are the     types  of  services  we perform</td>
    </tr>
    <tr>
      <td>If in the future NOTA were amended or     interpreted in a way that made us unable to include some of these costs in     the  amounts we charge our customers, it <font color="blue">could reduce</font> our revenues and     therefore  hurt  our  business</td>
    </tr>
    <tr>
      <td>It  is possible that more <font color="blue">restrictive</font>     interpretations or <font color="blue">expansions</font> of NOTA could be adopted in the <font color="blue">future which</font>     could  require  us to change one or more aspects of our business, at a     substantial cost, in order to continue to <font color="blue">comply with</font> this statute</td>
    </tr>
    <tr>
      <td>A variety of <font color="blue">additional local</font>, state, federal and <font color="blue">international government</font>     laws and <font color="blue">regulations</font> govern our business, including those relating to the     storage, handling, generation, manufacture and disposal of <font color="blue">medical wastes</font>     from  the  processing of tissue</td>
    </tr>
    <tr>
      <td>If we fail to conduct our business in     compliance  with  these  laws  and <font color="blue">regulations</font>, we could be subject to     <font color="blue">significant</font> liabilities</td>
    </tr>
    <tr>
      <td>We could be subject to <font color="blue">significant</font> liabilities     arising <font color="blue">from hazardous biological materials</font> for which our <font color="blue">insurance may</font> not     be adequate</td>
    </tr>
    <tr>
      <td>Moreover, such <font color="blue">insurance may</font> not always be available in the     <font color="blue">future on <font color="blue">commercially reasonable terms</font></font>, if at all</td>
    </tr>
    <tr>
      <td>If our <font color="blue">insurance proves</font>     to be inadequate to pay a <font color="blue">damage award</font>, we may not have <font color="blue">sufficient funds</font> to     do so, <font color="blue">which could harm</font> our <font color="blue">financial condition</font> and liquidity</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">success will depend</font> on</font> the <font color="blue">continued <font color="blue">acceptance</font></font> of our allograft and     <font color="blue">xenograft implants</font> and <font color="blue">technologies</font> by the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">new allograft</font> and <font color="blue">xenograft implants</font>, <font color="blue">technologies</font> or <font color="blue">enhancements</font> to     <font color="blue"><font color="blue">existing implants</font> may never</font> achieve broad market <font color="blue">acceptance</font>, which can be     <font color="blue">affected by numerous factors</font>, including:           •   lack of <font color="blue">clinical <font color="blue">acceptance</font></font> of our implants and <font color="blue">technologies</font>;           •   <font color="blue">introduction</font> of <font color="blue">competitive <font color="blue">tissue repair treatment</font> options which</font>     render our implants and <font color="blue">technologies</font> too expensive or obsolete;           •   lack of <font color="blue">availability</font> of third-party <font color="blue">reimbursement</font>; and           •   <font color="blue">difficult</font>y training surgeons in the use of our <font color="blue">tissue implants</font> and     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Market <font color="blue"><font color="blue">acceptance</font> will also depend on</font> our ability to <font color="blue">demonstrate</font> that our     existing and <font color="blue">new implants</font> and <font color="blue">technologies</font> are an <font color="blue">attractive alternative</font> to     <font color="blue">existing <font color="blue">tissue repair treatment</font> options</font></td>
    </tr>
    <tr>
      <td>Our ability to do so will depend     on surgeons’ evaluations of the clinical safety, efficacy, ease of use,     <font color="blue">re<font color="blue">liability</font></font>  and cost-<font color="blue">effective</font>ness of these <font color="blue">tissue repair options</font> and     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>For example, we believe that some in the <font color="blue">medical community</font>     have <font color="blue">lingering concerns over</font> the risk of <font color="blue">disease <font color="blue">transmission</font> through</font> the     use of <font color="blue">allografts</font></td>
    </tr>
    <tr>
      <td>Furthermore, we believe that even if the <font color="blue">medical community</font> generally accepts     our  implants  and  <font color="blue">technologies</font>,  <font color="blue">recommendations</font> and <font color="blue">endorsements by</font>     <font color="blue">influential surgeons will</font> be important to their <font color="blue">broad commercial success</font></td>
    </tr>
    <tr>
      <td>If     our implants and <font color="blue">technologies</font> are not <font color="blue">broadly accepted</font> in the marketplace,     we may not achieve a <font color="blue">competitive position</font> in the market</td>
    </tr>
    <tr>
      <td>Rapid <font color="blue">technological</font> changes <font color="blue">will affect us</font> and our customers, which could     result in <font color="blue">reduced demand</font> for our <font color="blue">allografts</font></td>
    </tr>
    <tr>
      <td><font color="blue">Technologies  </font>change  rapidly  in  our  industry</td>
    </tr>
    <tr>
      <td>For example, steady     <font color="blue">improvements</font> have been made in synthetic <font color="blue">human tissue</font> substitutes which     compete  with our <font color="blue">tissue implants</font></td>
    </tr>
    <tr>
      <td>Unlike <font color="blue">allografts</font>, <font color="blue">synthetic tissue</font>     <font color="blue">technologies</font> are not <font color="blue"><font color="blue">dependent</font> on</font> the <font color="blue">availability</font> of tissue</td>
    </tr>
    <tr>
      <td>If one of our     <font color="blue">competitors</font> <font color="blue">successfully</font> introduces synthetic <font color="blue">technologies</font> using recombinant     <font color="blue">technologies</font>, which stimulate the growth of <font color="blue">tissue surrounding</font> an implant,     it could result in a decline in demand for <font color="blue">tissue implants</font></td>
    </tr>
    <tr>
      <td>Although our     <font color="blue">growth strategy</font> contemplates introducing <font color="blue">new implants</font> and <font color="blue">technologies</font>, the     <font color="blue">development</font> of these <font color="blue">new implants</font> and <font color="blue">technologies</font> is a                                           15     ______________________________________________________________________    [51]Table of <font color="blue">Contents       </font>complex and <font color="blue">uncertain process</font>, requiring a <font color="blue">high level</font> of innovation, as well     as the ability to <font color="blue">accurately predict future <font color="blue">technology</font></font> and <font color="blue">market trends</font></td>
    </tr>
    <tr>
      <td>The implants we currently have in <font color="blue">development</font> will require <font color="blue">significant</font>     additional <font color="blue">development</font>, <font color="blue">investment</font> and testing</td>
    </tr>
    <tr>
      <td>We may need to undertake     costly and time-consuming efforts to achieve these <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>We may not be     able to respond <font color="blue"><font color="blue">effective</font>ly</font> to <font color="blue">technological</font> changes and <font color="blue">emerging industry</font>     standards, or to <font color="blue">successfully</font> identify, develop or support new <font color="blue">technologies</font>     or <font color="blue">enhancements</font> to <font color="blue">existing implants</font> in a timely and cost-<font color="blue">effective</font> manner,     if at all</td>
    </tr>
    <tr>
      <td>If we are unable to achieve the <font color="blue">improvements</font> in our implants     <font color="blue">necessary</font>  for  their <font color="blue">successful commercialization</font>, the demand for our     <font color="blue">implants will suffer</font></td>
    </tr>
    <tr>
      <td>We face intense competition, which could result in <font color="blue">reduced <font color="blue">acceptance</font></font> and     demand for our implants and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>The medical <font color="blue">technology</font>/bio<font color="blue">technology</font> industry is <font color="blue">intensely competitive</font></td>
    </tr>
    <tr>
      <td>We     <font color="blue"><font color="blue">compete with</font> companies</font> in the <font color="blue">United States </font>and <font color="blue">internationally</font> that engage     in the <font color="blue">development</font> and production of medical <font color="blue">technologies</font> and processes     including:           •   bio<font color="blue">technology</font>, orthopedic, pharmaceutical, biomaterial and other     companies;           •   academic and <font color="blue">scientific institutions</font>; and           •   public and private research <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue">competitors</font> have much greater financial, technical, research,     marketing, <font color="blue">distribution</font>, service and other <font color="blue">resources than</font> we have</td>
    </tr>
    <tr>
      <td>Moreover,     our  <font color="blue">competitors</font>  may offer a <font color="blue">broader array</font> of <font color="blue">tissue repair treatment</font>     products and <font color="blue">technologies</font> or may have <font color="blue">greater name <font color="blue">recognition</font> than</font> we do in     the marketplace</td>
    </tr>
    <tr>
      <td>For example, we <font color="blue">compete with</font> a number of divisions of     Johnson &amp; Johnson, a company with <font color="blue">significant</font>ly greater resources and brand     <font color="blue">recognition</font> than we have</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font>, including several <font color="blue">development</font>     stage companies, may develop or market <font color="blue">technologies</font> that are more <font color="blue">effective</font>     or <font color="blue">commercially attractive than ours</font>, or that may render our <font color="blue">technologies</font>     obsolete</td>
    </tr>
    <tr>
      <td>For example, the successful <font color="blue">development</font> of a <font color="blue">synthetic tissue</font>     product that <font color="blue">permits remodeling</font> of <font color="blue">bones could</font> result in a decline in the     demand for allograft-based products and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>If we do not manage the <font color="blue">medical release</font> of <font color="blue"><font color="blue">donor tissue</font> into processing</font> in     an <font color="blue">efficient manner</font>, it <font color="blue">could affect</font> our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>There are many <font color="blue">factors which affect</font> the level and timing of donor medical     releases, such as <font color="blue">effective</font>ness of <font color="blue">donor screening</font> performed by our donor     recovery  groups, the timely receipt, recording and review of required     <font color="blue">medical documentation</font>, and <font color="blue">employee loss</font> and turnover in our <font color="blue">medical records</font>     department</td>
    </tr>
    <tr>
      <td>Some of our donor recovery groups are also <font color="blue">processors</font> who     provide  us  with  partially processed tissues which they have already     determined to be <font color="blue">medically</font> suitable for processing</td>
    </tr>
    <tr>
      <td>Therefore, these sources     provide  a <font color="blue">higher level</font> of <font color="blue">documentation than</font> those that perform donor     <font color="blue">recovery alone</font></td>
    </tr>
    <tr>
      <td>Although we strive for the timely <font color="blue">medical release</font> of tissue,     while at the same time <font color="blue">maximizing safety</font> for our employees and for tissue     <font color="blue">recipients</font>, our <font color="blue"><font color="blue">internal policies</font> may sacrifice timely release</font> of tissue in     favor of safety</td>
    </tr>
    <tr>
      <td>We continue to review our <font color="blue">internal policies</font> in order to     provide the <font color="blue">best framework</font> for <font color="blue">medical release</font>s, however we can <font color="blue">provide no</font>     assurance that <font color="blue">releases will</font> occur <font color="blue">at levels which maximize</font> our processing     <font color="blue">efficiency</font> and minimize our cost per <font color="blue">allograft processed</font></td>
    </tr>
    <tr>
      <td>Negative <font color="blue">publicity concerning methods</font> of <font color="blue">human tissue</font> recovery and screening     of <font color="blue">donor tissue</font> in our industry <font color="blue">could reduce</font> demand for our <font color="blue">allografts</font> and     impact the supply of available <font color="blue">donor tissue</font></td>
    </tr>
    <tr>
      <td>Media reports or other <font color="blue">negative publicity</font> concerning both improper methods     of <font color="blue"><font color="blue">tissue recovery</font> from donors</font> and <font color="blue">disease <font color="blue">transmission</font> from donated tissue</font>     <font color="blue">could limit widespread <font color="blue">acceptance</font></font> of our <font color="blue">allografts</font></td>
    </tr>
    <tr>
      <td><font color="blue">Unfavorable </font>reports of     improper or illegal <font color="blue">tissue recovery</font> practices, both in the <font color="blue">United States </font>and     <font color="blue">internationally</font>, as well as <font color="blue">incidents</font> of <font color="blue">improperly</font> processed tissue leading     to <font color="blue">transmission</font> of disease, may broadly affect the rate of future tissue     donation and market <font color="blue">acceptance</font> of allograft <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>16     ______________________________________________________________________    [52]Table of <font color="blue">Contents       </font>Potential <font color="blue">patients may</font> not distinguish our <font color="blue">allografts</font>, <font color="blue">technologies</font> and the     <font color="blue">tissue recovery</font> and the <font color="blue">processing procedures</font> we have in place, from those     of  our <font color="blue">competitors</font> or others engaged in <font color="blue">tissue recovery</font></td>
    </tr>
    <tr>
      <td>In addition,     families of <font color="blue">potential donors may become reluctant</font> to agree to <font color="blue">donate tissue</font>     to for-profit tissue <font color="blue">processors</font></td>
    </tr>
    <tr>
      <td>If  our patents and the other means we use to protect our <font color="blue">intellectual</font>     property  prove  to  be  inadequate, our <font color="blue">competitors</font> could exploit our     <font color="blue">intellectual</font> property to compete more <font color="blue"><font color="blue">effective</font>ly</font> <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>The  law of patents and <font color="blue">trade secrets</font> is <font color="blue">constantly evolving</font> and often     <font color="blue">involves complex legal</font> and factual questions</td>
    </tr>
    <tr>
      <td>The US <font color="blue">government may deny</font>     or <font color="blue">significant</font>ly reduce the coverage we seek in our patent <font color="blue">applications</font>     before or after a patent is issued</td>
    </tr>
    <tr>
      <td>We therefore cannot be sure that any     <font color="blue">particular patent</font> we apply for will be issued, that the scope of the patent     <font color="blue">protection will</font> be <font color="blue">comprehensive enough</font> to <font color="blue">provide adequate protection from</font>     similar  <font color="blue">technologies</font>  which  may <font color="blue">compete with</font> ours, that <font color="blue">interference</font>     <font color="blue">proceedings</font> regarding any of our patent <font color="blue">applications</font> will not be filed, or     that we will achieve any other <font color="blue">competitive advantage from</font> a patent</td>
    </tr>
    <tr>
      <td>In     addition,  it is possible that one or more of our patents will be held     invalid if challenged or that others will claim rights in or ownership of     our patents and other <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>If any of these events occur, our     <font color="blue">competitors</font> may be able to use our <font color="blue">intellectual</font> property to compete more     <font color="blue"><font color="blue">effective</font>ly</font> <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>Because patent <font color="blue">applications</font> are <font color="blue">secret until patents</font> are <font color="blue">actually issued</font> (or     until  18  months  after  a <font color="blue">patent application</font> has been filed) and the     <font color="blue">publication</font> of <font color="blue">discoveries</font> in the scientific or <font color="blue">patent literature lags</font>     behind actual <font color="blue">discoveries</font>, we cannot be certain that our <font color="blue">patent application</font>     was the <font color="blue">first application filed covering</font> a <font color="blue">particular invention</font></td>
    </tr>
    <tr>
      <td>If another     party’s rights to an invention are superior to ours, we may not be able to     obtain a license to use that party’s invention on commercially reasonable     terms, if at all</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">competitors</font>, many of which have greater     <font color="blue">resources than</font> we do, could obtain patents that will prevent, limit or     <font color="blue">interfere with</font> our ability to make use of our <font color="blue">inventions either</font> in the     <font color="blue">United States </font>or in <font color="blue">international markets</font></td>
    </tr>
    <tr>
      <td>Further, the laws of some foreign     countries do not always protect our <font color="blue">intellectual</font> <font color="blue">property rights</font> to the same     extent  as  the  laws  of  the United States</td>
    </tr>
    <tr>
      <td><font color="blue">Litigation </font>or <font color="blue">regulatory</font>     <font color="blue">proceedings</font> in the <font color="blue">United States </font>or foreign countries also may be <font color="blue">necessary</font>     to enforce our patent or other <font color="blue">intellectual</font> <font color="blue">property rights</font> or to determine     the  scope  and validity of our <font color="blue">competitors</font>’ <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">proceedings</font> can be costly, result in <font color="blue">development</font> delays, and divert our     management’s attention from our business</td>
    </tr>
    <tr>
      <td>We also rely upon unpatented <font color="blue">proprietary</font> techniques and processes in tissue     recovery, research and <font color="blue">development</font>, tissue processing and <font color="blue">quality assurance</font></td>
    </tr>
    <tr>
      <td>It is possible that <font color="blue">others will in<font color="blue">dependent</font>ly</font> develop <font color="blue">technology</font> similar to     ours or <font color="blue">otherwise gain access</font> to or disclose our <font color="blue">proprietary</font> <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>We may not be able to <font color="blue">meaningfully protect</font> our rights in these <font color="blue">proprietary</font>     <font color="blue">technologies</font>, which would reduce our ability to compete</td>
    </tr>
    <tr>
      <td>In 1996, a law was passed in the <font color="blue">United States </font>that limits the <font color="blue">enforcement</font>     of <font color="blue">patents covering</font> the performance of surgical or <font color="blue"><font color="blue">medical procedures</font> on</font> a     human body</td>
    </tr>
    <tr>
      <td>This <font color="blue">law prevents medical practitioners</font> and <font color="blue">health care entities</font>     who  practice  these  procedures,  not <font color="blue">otherwise covered by</font> a patented     procedure, from being sued for <font color="blue">patent infringement</font></td>
    </tr>
    <tr>
      <td>Therefore, depending     upon how these <font color="blue">limitations</font> are <font color="blue">interpreted by</font> the courts, they could have a     material adverse effect on our ability to enforce any of our <font color="blue">proprietary</font>     methods or procedures deemed to be surgical or <font color="blue">medical procedures</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font> in part on our ability to operate <font color="blue">without infringing</font>     on or <font color="blue">misappropriating</font> the <font color="blue"><font color="blue">proprietary</font> rights</font> of others, and if we are     unable to do so we may be liable for damages</td>
    </tr>
    <tr>
      <td>We cannot be certain that US or foreign patents or patent <font color="blue">applications</font> of     other companies do not exist or will not be issued that would prevent us     from <font color="blue">commercializing</font> our <font color="blue">allografts</font> and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may sue</font>     us for infringing or <font color="blue">misappropriating</font> their patent or other <font color="blue">intellectual</font>     <font color="blue">property rights</font></td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual </font><font color="blue">property <font color="blue">litigation</font></font> is costly</td>
    </tr>
    <tr>
      <td>If we do not     prevail in <font color="blue">litigation</font>, in addition to any damages we might have to pay, we     could  be required to stop the <font color="blue">infringing activity</font> or obtain a license     requiring  us to make <font color="blue">royalty payments</font></td>
    </tr>
    <tr>
      <td>It is possible that a required     <font color="blue">license will</font> not be available to <font color="blue">us on commercially</font> acceptable terms, if at     all</td>
    </tr>
    <tr>
      <td>In addition, a                                           17     ______________________________________________________________________    [53]Table of <font color="blue">Contents       </font>required <font color="blue">license may</font> be non-exclusive, and therefore our <font color="blue">competitors</font> may     have access to the same <font color="blue">technology</font> licensed to us</td>
    </tr>
    <tr>
      <td>If we fail to obtain a     required license or are unable to <font color="blue">design around</font> another company’s patent, we     may be unable to make use of some of the affected <font color="blue">technologies</font> or distribute     the affected <font color="blue">allografts</font> which would negatively impact our revenues</td>
    </tr>
    <tr>
      <td>We or our <font color="blue">competitors</font> may be exposed to product <font color="blue">liability</font> claims which could     cause us to be liable for damages or cause investors to think we will be     liable for similar claims in the future</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of <font color="blue">allografts</font> and <font color="blue">technologies</font> for <font color="blue">human tissue</font> repair and     treatment  entails  an  <font color="blue">inherent risk</font> of product <font color="blue">liability</font> claims, and     substantial product <font color="blue">liability</font> claims may be asserted <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>We are     party to a number of legal <font color="blue">proceedings</font> related to product <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>We     currently have dlra20 million of product <font color="blue">liability</font> insurance to cover claims</td>
    </tr>
    <tr>
      <td>This amount of <font color="blue">insurance may</font> not be adequate for current claims if we are     not successful in our defenses, and <font color="blue">furthermore</font>, we may not have adequate     <font color="blue">insurance coverage</font> for any future claims that arise</td>
    </tr>
    <tr>
      <td>Moreover, insurance     covering  our  business  may  not always be available in the future on     <font color="blue">commercially reasonable terms</font>, if at all</td>
    </tr>
    <tr>
      <td>If our <font color="blue">insurance proves</font> to be     inadequate to pay a <font color="blue">damage award</font>, we may not have <font color="blue">sufficient funds</font> to do so,     which  would  harm our <font color="blue">financial condition</font> and liquidity</td>
    </tr>
    <tr>
      <td>In addition,     successful product <font color="blue">liability</font> claims made <font color="blue">against one</font> of our <font color="blue">competitors</font>     could cause claims to be made <font color="blue">against us</font> or expose us to a <font color="blue">perception</font> that     we  are  vulnerable to similar claims</td>
    </tr>
    <tr>
      <td>In addition, claims <font color="blue">against us</font>,     <font color="blue">regardless</font> of their merit or potential outcome, may also hurt our ability to     obtain <font color="blue">surgeon endorsement</font> of our <font color="blue">allografts</font> or to expand our business</td>
    </tr>
    <tr>
      <td>If we are not successful in expanding our <font color="blue">distribution</font> activities into     <font color="blue">international markets</font>, we will not be able to pursue one of our strategies     for increasing our revenues</td>
    </tr>
    <tr>
      <td>Our  current and planned international <font color="blue">distribution</font> strategies vary by     market, as well as within each country in which we operate</td>
    </tr>
    <tr>
      <td>For example, we     <font color="blue">distribute only</font> a portion of our line of <font color="blue">allografts</font> within each country</td>
    </tr>
    <tr>
      <td>Our     international <font color="blue">operations</font> will be subject to a number of risks which may vary     from the risks we face in the United States, including:           •   the need to obtain <font color="blue">regulatory</font> approvals in <font color="blue">additional foreign</font>     countries before we can offer our implants and <font color="blue">technologies</font> for use;           •   longer <font color="blue">distribution</font>-to-collection cycles, as well as <font color="blue">difficult</font>y in     <font color="blue">collecting amounts owed</font> to us;           •   <font color="blue">dependence on local distributors</font>;           •   limited protection of <font color="blue">intellectual</font> <font color="blue">property rights</font>;           •   <font color="blue">fluctuations</font> in the values of <font color="blue">foreign currencies</font>; and           •   political and <font color="blue">economic instability</font></td>
    </tr>
    <tr>
      <td>The value of our <font color="blue">investment</font> in Organ Recovery Systems, Inc</td>
    </tr>
    <tr>
      <td>is <font color="blue"><font color="blue">dependent</font> on</font>     the <font color="blue">financial success</font> of this venture</td>
    </tr>
    <tr>
      <td>We own 1cmam285cmam347 shares of <font color="blue">convertible preferred stock issued by</font> Organ     Recovery Systems, Inc, or ORS, a privately held company, for which the     purchase  price was dlra5dtta25 million</td>
    </tr>
    <tr>
      <td>ORS is organized for the purpose of     advancing organ <font color="blue">transplantation</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td><font color="blue">Realization </font>of our <font color="blue">investment</font> in     ORS  is  <font color="blue">dependent</font>  upon ORS’s <font color="blue">successful execution</font> of its operational     strategies and the continued industry <font color="blue">acceptance</font> of its current and future     product <font color="blue">development</font>s</td>
    </tr>
    <tr>
      <td>If ORS does not <font color="blue">successfully</font> execute its operational     strategies  and  recognize  long-term  <font color="blue">profitability</font>, the value of our     <font color="blue">investment</font> could be <font color="blue">impaired which could</font> have a negative effect on our     <font color="blue">financial statements</font> for the period in which the <font color="blue">impairment</font> occurs</td>
    </tr>
  </tbody>
</table>